Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UroGen Pharma Ltd.URGN · Entity 4466 | General Counsel | September 07, 2026 | September 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UroGen Pharma Ltd.
Report date September 07, 2026 · Filed September 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 53,141 |
Ending reported balance
After 2026-09-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-07 · Exercise / conversion · Acquired 3,334 · Balance 54,660 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Row 2 · 2026-09-08 · Sale · Disposed 1,519 · Balance 53,141 F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-07 · Exercise / conversion · Disposed 3,334 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer.
F2: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units.
F3: The reporting person was granted RSUs on September 7, 2023 representing 10,000 ordinary shares. The RSUs will vest in three equal annual installments from September 7, 2024.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · derivative · entry 6 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F4 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. F4 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2022 representing 7,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2023. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · derivative · entry 5 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 834 Underlying: Ordinary Shares · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 1,227 | $10.12 | $12,417.24 |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · nonDerivative · entry 4 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,873 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 2,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · nonDerivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 409 | $10.12 | $4,139.08 |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,600 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 18:04 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-002338 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 15:40 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001437749-22-021776 · rdgdoc.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,334 Underlying: Ordinary Shares · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vest in three equal annual installments on November 30, 2021, August 31, 2022 and August 31, 2023. F3 · derivative.expiration_date: The reporting person was granted RSUs on August 31, 2020 representing 25,000 ordinary shares. The RSUs vest in three equal annual installments on November 30, 2021, August 31, 2022 and August 31, 2023. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 15:40 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,606 | $7.21 | $25,999.26 |
DisclosureSEC source: 0001437749-22-021776 · rdgdoc.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,176 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 15:40 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-021776 · rdgdoc.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,782 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.72 | $0.00 |
DisclosureSEC source: 0001209191-22-006387 · doc4.xml · derivative · entry 5 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Ordinary Shares · 30,000 shares Expires 2032-01-31 F5 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006387 · doc4.xml · derivative · entry 4 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Ordinary Shares · 7,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F4 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. F4 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2023, January 31, 2024 and January 31, 2025. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-006387 · doc4.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,667 Underlying: Ordinary Shares · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. F3 · derivative.expiration_date: The reporting person was granted RSUs on January 31, 2021 representing 2,500 ordinary shares. The RSUs will vest in three equal annual installments from January 31, 2022. Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 414 | $7.58 | $3,138.12 |
DisclosureSEC source: 0001209191-22-006387 · doc4.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,449 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| January 31, 2022 Filed Feb 2, 2022 21:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-006387 · doc4.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,863 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:16 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionRestricted Stock Units · Derivative | 8,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-067440 · doc4.xml · derivative · entry 3 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,667 Underlying: Ordinary Shares · 8,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer F3 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of November 30, 2021, August 31, 2022 and August 31, 2023. F3 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of November 30, 2021, August 31, 2022 and August 31, 2023. Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:16 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | SaleOrdinary Shares | 3,803 | $12.03 | $45,750.09 |
DisclosureSEC source: 0001209191-21-067440 · doc4.xml · nonDerivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,030 F2 · shares: Represents shares sold to satisfy withholding tax obligations upon the settlement of restricted stock units Read SEC document |
| November 30, 2021 Filed Dec 2, 2021 18:16 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | Exercise / conversionOrdinary Shares | 8,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-067440 · doc4.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,833 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer Read SEC document |
| June 05, 2021 Filed Jun 8, 2021 18:33 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001209191-21-038842 · doc4.xml · derivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-05-31 F1 · derivative.exercise_date: 1/3 of the shares underlying the stock options will vest on each of June 1, 2022, June 1, 2023 and June 1, 2024. Read SEC document |
| May 17, 2021 Filed May 18, 2021 15:35 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | PurchaseCommon Stock | 2,500 | $15.71 | $39,275.00 |
DisclosureSEC source: 0001209191-21-033399 · doc4.xml · nonDerivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $15.675 and 15.76, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 20:55 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Units · Derivative | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-006709 · doc4.xml · derivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Underlying: Ordinary Shares · 2,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024. F3 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024. Read SEC document |
| January 31, 2021 Filed Feb 2, 2021 20:55 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $22.07 | $0.00 |
DisclosureSEC source: 0001209191-21-006709 · doc4.xml · derivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Ordinary Shares · 8,000 shares Expires 2031-01-30 F1 · derivative.exercise_date: 1/3 of the shares underlying the stock option will vest on each of January 31, 2022, January 31, 2023 and January 31, 2024. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:35 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-053632 · doc4a.xml · derivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share of the Issuer. F1 · date: The stock options and restricted stock units represented on the original Form 4 were not granted to the reporting person until October 1, 2020, following approval by the Issuer's Compensation Committee on that date. F4 · derivative.exercise_date: 1/3 of the shares underlying the restricted stock units will vest on each of August 31, 2021, August 31, 2022 and August 31, 2023. F4 · derivative.expiration_date: 1/3 of the shares underlying the restricted stock units will vest on each of August 31, 2021, August 31, 2022 and August 31, 2023. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 20:35 UTC Amendment | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $19.66 | $0.00 |
DisclosureSEC source: 0001209191-20-053632 · doc4a.xml · derivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2030-09-30 F1 · date: The stock options and restricted stock units represented on the original Form 4 were not granted to the reporting person until October 1, 2020, following approval by the Issuer's Compensation Committee on that date. F2 · derivative.exercise_date: 1/3 of the shares underlying the stock option will vest on each of August 31, 2021, August 31, 2022 and August 31, 2023. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 16:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantRestricted Stock Unit · Derivative | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-049937 · doc4.xml · derivative · entry 2 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Ordinary Shares · 25,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one ordinary share of the Issuer. F3 · derivative.exercise_date: 33.33% of the restricted stock units ("RSUs") will vest on September 9, 2021, 33.33% of the remaining RSUs will vest on September 9, 2022, and 33.34% of the remaining RSUs will vest on September 9, 2023. F3 · derivative.expiration_date: 33.33% of the restricted stock units ("RSUs") will vest on September 9, 2021, 33.33% of the remaining RSUs will vest on September 9, 2022, and 33.34% of the remaining RSUs will vest on September 9, 2023. Read SEC document |
| September 09, 2020 Filed Sep 10, 2020 16:14 UTC | UroGen Pharma Ltd. URGN · Entity 4466 | GrantEmployee Stock Option (right to buy) · Derivative | 60,000 | $0.00 Strike: $21.38 | $0.00 |
DisclosureSEC source: 0001209191-20-049937 · doc4.xml · derivative · entry 1 Smith Jason Drew · CIK 0001821479 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 60,000 shares Expires 2030-09-08 F1 · derivative.exercise_date: 33.33% of the shares underlying the stock option will vest on September 9, 2021, 33.33% of the remaining shares underlying the stock option will vest on September 9, 2022, and 33.34% of the remaining shares shares underlying the stock option will vest on September 9, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.